Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
    12.
    发明申请
    Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders 审中-公开
    炔丙基氮氧化物和二氢化茚基氮氧化物及其用于治疗神经系统疾病和病症的用途

    公开(公告)号:US20060025446A1

    公开(公告)日:2006-02-02

    申请号:US11191212

    申请日:2005-07-26

    IPC分类号: C07D211/06 A61K31/445

    CPC分类号: C07D211/94

    摘要: Disclosed are compounds having the structure: wherein Z is —OH or —O•; and A is: wherein X and Y are independently NR1 or O, where R1 is H or C1-C4 alkyl; and R2 is H, C1-C4 alkyl or t-butoxycarbonyl, wherein W is C3-C4 alkynyl; and R1 is H or C1-C4 alkyl, or wherein R1 is H, C1-C4 alkyl, or C3-C4 alkynyl; and R3 is H, OH, O(C1-C4 alkyl), or a halogen, optically active enantiomers, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions containing such compounds or salts, and processes for their preparation. The subject invention also provides methods of alleviating symptoms of neurologic, autoimmune, and inflammatory disorders caused by the presence of reactive oxygen species, methods of preventing oxidation of lipids, proteins, or deoxyribonucleic acids on a cellular level, and methods of protecting human red blood cells from lysis by O2 radicals.

    摘要翻译: 公开了具有以下结构的化合物:其中Z是-OH或-O。 A是:其中X和Y独立地是NR 1或O,其中R 1是H或C 1 -C 4 烷基; R 2是H,C 1 -C 4烷基或叔丁氧基羰基,其中W是C 3 H 3, -C 4炔基; 且R 1是H或C 1 -C 4烷基,或其中R 1是H,C 1 -C 6烷基, C 1 -C 4烷基或C 3 -C 4炔基; C 1 -C 4烷基或C 3 -C 4炔基; 和R 3是H,OH,O(C 1 -C 4烷基)或卤素,旋光对映异构体,药学上可接受的盐 的化合物,含有这些化合物或盐的药物组合物,及其制备方法。 本发明还提供减轻由活性氧的存在引起的神经系统,自身免疫性和炎症性疾病的症状的方法,在细胞水平上防止脂质,蛋白质或脱氧核糖核酸的氧化的方法,以及保护人类红血液的方法 细胞由O 2自由基裂解。

    PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS
    16.
    发明申请
    PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS 审中-公开
    丙氨酰胺衍生物和丙氨酰胺四环素衍生物作为脑选择性MAO抑制剂

    公开(公告)号:US20090131535A1

    公开(公告)日:2009-05-21

    申请号:US12357177

    申请日:2009-01-21

    摘要: The subject invention provides derivatives of propargylamino indan (PAI) and propargylamino tetralin that selectively inhibit monoamine oxidase (MAO) in the brain, having the structure: wherein R1 is OC(O)R9 and R2 is H, wherein R9 is branched or unbranched C1 to C6 alkyl, aryl, or aralkyl, or R1 is OC(O)R4 and R2 is OC(O)R4, wherein R4 is branched or unbranched C1 to C6 alkyl, aryl, aralkyl or NR5R6, wherein R5 and R6 are each independently H, C1 to C8 alkyl, C6 to C12 aryl, C6 to C12 aralkyl or C6 to C12 cycloalkyl, each optionally substituted; wherein R3 is H or C1 to C6 alkyl; wherein n is 0 or 1; and wherein m is 1 or 2, or a pharmaceutically acceptable salt thereof. Additionally, the subject invention provides methods of treating neurological disorders using these compounds, uses of these compounds for the manufacture of medicaments for treating neurological disorders and processes for synthesis of these compounds.

    摘要翻译: 本发明提供了选择性抑制脑中单胺氧化酶(MAO)的炔丙基氨基茚满(PAI)和炔丙基氨基四氢萘的衍生物,其结构如下:其中R1是OC(O)R9且R2是H,其中R9是支链或非支链C1 或C 1 -C 6烷基,芳基或芳烷基,或R 1为OC(O)R 4且R 2为OC(O)R 4,其中R 4为支链或非支链C1至C6烷基,芳基,芳烷基或NR5R6,其中R5和R6各自独立地为 H,C 1至C 8烷基,C 6至C 12芳基,C 6至C 12芳烷基或C 6至C 12环烷基,各自任选取代; 其中R3是H或C1-C6烷基; 其中n为0或1; 并且其中m为1或2,或其药学上可接受的盐。 另外,本发明提供了使用这些化合物治疗神经障碍的方法,这些化合物用于制备用于治疗神经障碍的药物的用途和用于合成这些化合物的方法。

    Derivatives of tetramethylcyclopropane
    19.
    发明授权
    Derivatives of tetramethylcyclopropane 失效
    四甲基环丙烷的衍生物

    公开(公告)号:US5880157A

    公开(公告)日:1999-03-09

    申请号:US687486

    申请日:1996-11-25

    CPC分类号: C07C237/22 C07C233/58

    摘要: The present invention relates to derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid (TMCA) of general formula (I), ##STR1## wherein R is lower alkyl group (C.sub.1 -C.sub.6), an aryl group, an aralkyl group or an amide of general formula (II), ##STR2## where R.sub.1 and R.sub.2 are the same or different and may be hydrogen, a alkyl group (C.sub.1 -C.sub.6), an aryl group or an aralkyl group, and n=0-3, to their racemic mixtures and the D and L enantiomers. The invention also relates to processes for the preparation of said compounds and for pharmaceutical preparations comprising the same. The new compounds show improved activity against epilepsy.

    摘要翻译: PCT No.PCT / US95 / 01388 Sec。 371日期:1996年11月25日 102(e)日期1996年11月25日PCT提交1995年2月8日PCT公布。 公开号WO95 / 21814 日期:1995年8月17日本发明涉及通式(I)的2,2,3,3-四甲基环丙烷羧酸(TMCA),其中R是低级烷基(C1-C6) ,芳基,芳烷基或通式(II)的酰胺,其中R 1和R 2相同或不同并且可以是氢,烷基(C 1 -C 6),芳基 或芳烷基,n = 0-3,与其外消旋混合物和D和L对映体。 本发明还涉及制备所述化合物和包含其的药物制剂的方法。 新化合物显示改善的针对癫痫的活性。